Evidence map›Paper›PMID 38766663›Full record

ArticleInternational journal of nanomedicine2024

Combined Ferritin Nanocarriers with ICG for Effective Phototherapy Against Breast Cancer.

Leopoldo Sitia, Paola Saccomandi, Leonardo Bianchi, Marta Sevieri, Cristina Sottani, Raffaele Allevi, Elena Grignani, Serena Mazzucchelli, Fabio Corsi

Abstract read
In one paragraph

Article in International journal of nanomedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Leopoldo Sitia *Department of Biomedical and Clinical Sciences, Università degli studi di Milano, Milan, Italy.ORCID 0000-0002-7268-4056
Paola Saccomandi *Department of Mechanical Engineering, Politecnico di Milano, Milan, Italy.ORCID 0000-0003-4236-8033
Leonardo BianchiDepartment of Mechanical Engineering, Politecnico di Milano, Milan, Italy.ORCID 0000-0001-6100-0862
Marta SevieriDepartment of Biomedical and Clinical Sciences, Università degli studi di Milano, Milan, Italy.ORCID 0000-0003-2017-641X
Cristina SottaniEnvironmental Research Center, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy.ORCID 0000-0001-9103-7367
Raffaele AlleviDepartment of Biomedical and Clinical Sciences, Università degli studi di Milano, Milan, Italy.ORCID 0000-0002-9904-0947
Elena GrignaniEnvironmental Research Center, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy.ORCID 0000-0002-3710-1409
Serena MazzucchelliDepartment of Biomedical and Clinical Sciences, Università degli studi di Milano, Milan, Italy.ORCID 0000-0001-6904-8895
Fabio CorsiDepartment of Biomedical and Clinical Sciences, Università degli studi di Milano, Milan, Italy.ORCID 0000-0002-6469-4086

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Photodynamic Therapy (PDT) is a promising, minimally invasive treatment for cancer with high immunostimulatory potential, no reported drug resistance, and reduced side effects. Indocyanine Green (ICG) has been used as a photosensitizer (PS) for PDT, although its poor stability and low tumor-target specificity strongly limit its efficacy. To overcome these limitations, ICG can be formulated as a tumor-targeting nanoparticle (NP). Methods: We nanoformulated ICG into recombinant heavy-ferritin nanocages (HFn-ICG). HFn has a specific interaction with transferrin receptor 1 (TfR1), which is overexpressed in most tumors, thus increasing HFn tumor tropism. First, we tested the properties of HFn-ICG as a PS upon irradiation with a continuous-wave diode laser. Then, we evaluated PDT efficacy in two breast cancer (BC) cell lines with different TfR1 expression levels. Finally, we measured the levels of intracellular endogenous heavy ferritin (H-Fn) after PDT treatment. In fact, it is known that cells undergoing ROS-induced autophagy, as in PDT, tend to increase their ferritin levels as a defence mechanism. By measuring intracellular H-Fn, we verified whether this interplay between internalized HFn and endogenous H-Fn could be used to maximize HFn uptake and PDT efficacy. Results: We previously demonstrated that HFn-ICG stabilized ICG molecules and increased their delivery to the target site in vitro and in vivo for fluorescence guided surgery. Here, with the aim of using HFn-ICG for PDT, we showed that HFn-ICG improved treatment efficacy in BC cells, depending on their TfR1 expression. Our data revealed that endogenous H-Fn levels were increased after PDT treatment, suggesting that this defence reaction against oxidative stress could be used to enhance HFn-ICG uptake in cells, increasing treatment efficacy. Conclusion: The strong PDT efficacy and peculiar Trojan horse-like mechanism, that we revealed for the first time in literature, confirmed the promising application of HFn-ICG in PDT.

Indexed as

Breast NeoplasmsIndocyanine GreenNanoparticlesPhotochemotherapyPhotosensitizing AgentsAntigens, CDApoferritinsCell Line, TumorCell SurvivalDrug CarriersFemaleFerritinsHumansMCF-7 CellsReceptors, TransferrinAntigens, CDApoferritinsCD71 antigenDrug CarriersFerritinsIndocyanine GreenPhotosensitizing AgentsReceptors, Transferrinbreast cancerheavy-ferritin nanocagesindocyanine greenphotodynamic therapytumor-targeted nanoparticles

Identifiers

PMID38766663
PMCPMC11102096

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.